10-Q: Bioxytran Faces Going Concern Doubts Amid Rising Liabilities

Bioxytran's Q3 2025 report reveals significant liquidity challenges and a going concern warning, despite increased R&D and recent capital raise efforts.

Summary

• Reported a net loss of $1,600,922 for the nine months ended September 30, 2025, a slight improvement from $1,614,543 in the prior year period.
• Cash balance increased to $14,499 as of September 30, 2025, from $5,154 at December 31, 2024.
• Total liabilities significantly increased to $3,060,937 from $1,930,642 over the same period.
• Accumulated deficit grew to $20,522,092 as of September 30, 2025, from $18,921,169 at December 31, 2024.
• Net working capital remained negative, worsening to $(3,046,438) from $(1,925,488).
• Research and development expenses surged to $452,000 for the nine months ended September 30, 2025, compared to $78,000 in the prior year.
• The company raised $315,680 in financing activities during the nine months ended September 30, 2025, including $13,353 from stock subscriptions and $302,327 from short-term loans.
• Subsequent to the quarter, a private placement offering closed on November 14, 2025, raising $430,000 by issuing 8,600,000 common shares and 8,600,000 warrants.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a "going concern" warning, and a rapidly increasing accumulated deficit and total liabilities. While R&D spending increased and some clinical milestones are anticipated, the fundamental financial health is highly precarious, and significant dilution is an ongoing risk. The recent capital raise is insufficient to address the stated funding needs.

Positives

• Net loss for the nine months ended September 30, 2025, slightly improved to $(1,600,922) compared to $(1,614,543) in the prior year.
• Cash balance increased to $14,499 as of September 30, 2025, from $5,154 at December 31, 2024.
• Research and development expenses significantly increased to $452,000 for the nine months ended September 30, 2025, indicating continued investment in product pipeline.
• Successful animal testing of BXT-25 showed non-toxicity and full recovery in Swiss Albino mice.
• IND for ProLectin-M (oral) in the US (PROTECT trial) was approved by the FDA on August 21, 2023, with the trial expected to start in Q4 2025.
• INDs for ProLectin-I (IV) and ProLectin-F in India were issued on January 27, 2023, with trials expected to start in Q4 2025.
• Recruitment for the Phase 1b/2a ProLectin-M trial in India was completed on May 1, 2025.

Negatives

• Substantial doubt about the company's ability to continue as a going concern due to insufficient capital resources.
• Accumulated deficit increased to $20,522,092 as of September 30, 2025.
• Net working capital worsened to negative $3,046,438 as of September 30, 2025.
• Total liabilities significantly increased to $3,060,937 as of September 30, 2025, from $1,930,642 at December 31, 2024.
• Derivative liability increased significantly to $419,206 from $186,652, representing 35.8% of the debt principal and highlighting potential equity dilution.
• EPS worsened to $(0.02) for the nine months ended September 30, 2025, from $(0.01) in the prior year, despite a slightly lower net loss, due to changes in weighted average shares outstanding.
• Net cash used in operating activities increased to $(289,484) for the nine months ended September 30, 2025, indicating higher cash burn.
• The company's current cash on hand ($14,499) is not sufficient to fund projected operating requirements through November 2025.
• Management notes difficulty in raising funds without heavily discounting the price and diluting shareholders due to a deflated stock price on OTC Markets.

Risks

• Going Concern Risk: The company's current cash ($14,499) and negative working capital ($3,046,438) raise substantial doubt about its ability to continue operations beyond November 2025 without additional funding.
• Funding Risk: There is no assurance that additional capital through private placements or public offerings will be available on acceptable terms or be sufficient to complete development activities or sustain operations.
• Dilution Risk: Conversion of outstanding convertible notes (totaling $1,046,433 including interest) with a price adjustment feature (120% of price difference if market price is below $0.13) could lead to substantial dilution for existing shareholders.
• Stock Price Volatility: The derivative liability is sensitive to stock price volatility, with a 20% increase in volatility potentially increasing the liability by $19,074.
• Operational Delays: Funding significantly less than the required $3,700,000 for 15 months will delay the development of technology and business.
• Internal Control Weaknesses: Material weaknesses in internal control over financial reporting, specifically lack of segregation of duties and inadequate review processes, could lead to material misstatements in financial statements.
• Reliance on Affiliates: Significant loans ($541,405 principal, $33,707 accrued interest) and un-issued shares ($60,894) are owed to affiliates, indicating reliance on related parties for financing.
• Litigation Risk: The company may become involved in legal proceedings and claims in the normal course of business.

Future Outlook

The company anticipates needing at least $3,700,000 to fund operations for the next 15 months, with less funding potentially delaying technology and business development. Management plans to seek additional capital through private placements and public offerings. Clinical trials for ProLectin-M (oral) in the US and ProLectin-I (IV) and ProLectin-F in India are expected to commence in Q4 2025. Results from the Phase 1b/2a ProLectin-M trial in India are scheduled for publication within 90 days of May 1, 2025, with a Phase 3 trial planned if results are positive. A 14-day repeated dose toxicity study for BXT-25 in rabbits and rats is the next step following successful animal testing.

Management Comments

• "We do not currently have sufficient capital resources to fund operations."
• "We believe that if we can raise $3,700,000, we will have sufficient working capital to develop our business over the next approximately fifteen (15) months."
• "If we fail to obtain such additional financing on a timely basis, the 2021 Holders may convert the 2021 Notes and sell the underlying shares, which may result in significant dilution to shareholders due to the conversion discount, as well as a significant decrease in our stock price."
• "Without such additional capital or the establishment of strategic relationships with established pharmaceutical companies, the Company may be required to cease operations."
• "These conditions raise substantial doubt about the Companys ability to continue as a going concern."
• "Despite the ongoing promotional activities, the Company still struggle with a deflated stock price on OTC Markets which makes it very difficult to raise funds without heavily discounting the price and diluting the shareholders."

Industry Context

Bioxytran operates in the highly capital-intensive and risky clinical-stage pharmaceutical sector, focusing on hypoxia and viral diseases. The company's pipeline, including BXT-25 for stroke and ProLectin-M/I/F for COVID-19 and related conditions, positions it in competitive therapeutic areas. The significant increase in R&D expenses reflects the typical investment required for drug development, while the ongoing need for substantial capital raises and the "going concern" warning are common challenges for early-stage biotech firms without revenue-generating products. The reliance on private placements and the struggle with a "deflated stock price on OTC Markets" highlight the difficulties in securing funding in this environment, especially for companies not yet in late-stage trials or commercialization.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The company may become involved in certain legal proceedings and claims which arise in the normal course of business.

Related Party Transactions

• The company holds a License Agreement for a medical device with an affiliated company of which the company's officers hold a majority interest, incurring a yearly maintenance cost of $5,000.
• Loan agreements with three affiliates total $541,405 in principal and $33,707 in accrued interest as of September 30, 2025.
• Officers forfeited $941,890 in payroll and affiliated expenses during the first nine months of 2025, with $214,780 accrued in the prior year and $727,110 reversed in current year general and administrative expenses.
• Accrued payroll due to the CEO ($105,000), CFO ($78,750), and CCO ($78,750) as of September 30, 2025.
• Un-issued shares liability to affiliates of $60,894 for board and committee meeting attendance during the second and third quarters of 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk from convertible notes and future capital raises due to the company's deflated stock price and urgent funding needs. The "going concern" warning poses a substantial risk to investment value.
• Employees (Executive Officers): Employment contracts include substantial severance packages (three times annual salary plus bonus) upon termination, and continued health coverage for 12 months, and outplacement services up to $50,000, which could be a significant liability for the company. Officers also forfeited a large amount of payroll ($941,890) in 2025.
• Creditors (Convertible Note Holders, Affiliates): The company has substantial outstanding debt, including $1,046,433 in convertible notes and $541,405 in loans from affiliates, with no assurance of funds to pay off these obligations. The derivative liability adds complexity to the convertible debt.
• Customers/Patients (Future): Delays in drug development due to insufficient funding could impact the availability of potential treatments for stroke, COVID-19, and lung fibrosis.

Next Steps

• Conduct a 14-day repeated dose toxicity study for BXT-25 using New Zealand Rabbits and Wistar Rats.
• Publish results from the Phase 1b/2a ProLectin-M trial in India and submit the report to the CDSCO within 90 days of May 1, 2025.
• Schedule a Phase 3 clinical trial with the CDSCO for ProLectin-M, provided positive trial results.
• Start the PROTECT clinical trial (ProLectin-M for COVID-19) in the US in Q4 2025.
• Start clinical trials for ProLectin-I (IV treatment for SARS-CoV-2/Long Covid) and ProLectin-F (lung-fibrosis) in India in Q4 2025.
• Seek additional capital through private placements and public offerings of common stock.
• Develop and implement a plan to further extend payables, reduce overhead, or scale back the current business plan if unable to raise sufficient funds.
• Hire accounting personnel with requisite knowledge to improve internal controls and address material weaknesses.

Key Dates

Recommendation

The company explicitly states "substantial doubt about the Company's ability to continue as a going concern" and has a negative working capital of over $3 million and an accumulated deficit exceeding $20 million. Total liabilities have significantly increased, and the company's cash on hand is insufficient for operations beyond the immediate future. While R&D is ongoing, the severe financial distress, high dilution risk from convertible debt and future capital raises, and material weaknesses in internal controls present an extremely high-risk profile. The recent $430,000 capital raise is a fraction of the $3.7 million needed for 15 months of operations, indicating persistent funding challenges and likely further dilution.

Keywords

Biotechnology, Pharmaceutical, Clinical Stage, Hypoxia, Stroke Treatment, COVID-19 Treatment, Drug Development, SEC Filing, 10-Q, Going Concern, Convertible Debt, Dilution, R&D, BXT-25, ProLectin-M, ProLectin-I, ProLectin-F, OTC Markets